Establishing Cultures Of Pig Tracheal Gland Cells To Analyze The Porcine Model Of Cystic Fibrosis

Author(s):  
Marrah E. Lachowicz-Scroggins ◽  
Rachel Borthwell ◽  
Jonathan Widdicombe
2000 ◽  
Vol 164 (6) ◽  
pp. 3377-3384 ◽  
Author(s):  
Olivier Tabary ◽  
Sandie Escotte ◽  
Jean Paul Couetil ◽  
Dominique Hubert ◽  
Daniel Dusser ◽  
...  

Author(s):  
W. Kammouni ◽  
D. Naı̈mi ◽  
W. Renaud ◽  
N. Bianco ◽  
C. Figarella ◽  
...  

2016 ◽  
Vol 311 (4) ◽  
pp. L779-L787 ◽  
Author(s):  
Stephen T. Ballard ◽  
Jessica W. Evans ◽  
Holly S. Drag ◽  
Michele Schuler

This study evaluated the pulmonary pathophysiology of pigs with transgenic CFTR “gut-corrected” cystic fibrosis (CF). Four sows produced 18 piglets of which 11 were stillborn, with only 2 animals surviving beyond 2 wk. Failure to survive beyond the neonatal period by five piglets was judged to result from metabolic dysfunction related to genetic manipulation for CFTR gut expression or due to cloning artifact. Plasma analysis showed very low plasma proteins, highly elevated liver enzymes, and severe acidosis. All surviving offspring received furosemide for systemic edema. Physiologic evaluation was performed with lung tissues from the two surviving pigs. Both acetylcholine and forskolin induced mucous liquid secretion that was significantly lower in bronchi of pigs with CF than those without CF. The percent of nonvolatile solids in mucus secreted from CF bronchi was elevated following acetylcholine or forskolin treatment. Mucociliary transport in excised tracheas was reduced in the CF tracheas relative to non-CF tracheas. The diameter of tracheas in pigs with CF was less than that of pigs without CF despite their greater body weight. Despite exhibiting severe metabolic dysfunction during the neonatal period, this CF animal model appears to express important characteristics of human CF pulmonary disease.


Author(s):  
Xiaopeng Li ◽  
Philip Karp ◽  
Peter Taft ◽  
Alejandro Pezzulo ◽  
David Stoltz ◽  
...  

2005 ◽  
Vol 7 (11) ◽  
pp. 1439-1449 ◽  
Author(s):  
Sonia Bastonero ◽  
Myriem Gargouri ◽  
Sandrine Ortiou ◽  
Jean-Louis Guéant ◽  
Marc D. Merten

Antioxidants ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1936
Author(s):  
Javier Checa ◽  
Itziar Martínez-González ◽  
Maria Maqueda ◽  
Jose Luis Mosquera ◽  
Josep M. Aran

Recurrent infection-inflammation cycles in cystic fibrosis (CF) patients generate a highly oxidative environment, leading to progressive destruction of the airway epithelia. The identification of novel modifier genes involved in oxidative stress susceptibility in the CF airways might contribute to devise new therapeutic approaches. We performed an unbiased genome-wide RNAi screen using a randomized siRNA library to identify oxidative stress modulators in CF airway epithelial cells. We monitored changes in cell viability after a lethal dose of hydrogen peroxide. Local similarity and protein-protein interaction network analyses uncovered siRNA target genes/pathways involved in oxidative stress. Further mining against public drug databases allowed identifying and validating commercially available drugs conferring oxidative stress resistance. Accordingly, a catalog of 167 siRNAs able to confer oxidative stress resistance in CF submucosal gland cells targeted 444 host genes and multiple circuitries involved in oxidative stress. The most significant processes were related to alternative splicing and cell communication, motility, and remodeling (impacting cilia structure/function, and cell guidance complexes). Other relevant pathways included DNA repair and PI3K/AKT/mTOR signaling. The mTOR inhibitor everolimus, the α1-adrenergic receptor antagonist doxazosin, and the Syk inhibitor fostamatinib significantly increased the viability of CF submucosal gland cells under strong oxidative stress pressure. Thus, novel therapeutic strategies to preserve airway cell integrity from the harsh oxidative milieu of CF airways could stem from a deep understanding of the complex consequences of oxidative stress at the molecular level, followed by a rational repurposing of existing “protective” drugs. This approach could also prove useful to other respiratory pathologies.


2020 ◽  
Vol 100 (11) ◽  
pp. 1388-1399
Author(s):  
Keyan Zarei ◽  
Mallory R. Stroik ◽  
Nick D. Gansemer ◽  
Andrew L. Thurman ◽  
Lynda S. Ostedgaard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document